Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCORT-1st: Camrelizumab plus chemotherapy in advanced esophageal squamous cell carcinoma
NCT03691090Phase 3Completed
- Sponsor
- Hengrui
- Start
- Dec 2018
- Primary completion
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing SHR-1210 + Chemo with Placebo + Chemo (2 arms). Primary endpoints: Progression-Free Survival assessed by Independent Review Committee up to 22 months and Overall Survival up to 22 months. Started Dec 2018; status: completed.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03691090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03691090.